Compare Amylx Pharmaceuticals Inc (AMLX) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.8. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | FEPI | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $49.54 |
52-Week Low | $7.82 | $37.98 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
FEPI trades at $41.80, showing slight daily weakness with a 0.17% decline. The ETF maintains a bullish technical signal with strong moving average support and weekly dividend distributions averaging $0.20-0.21. Recent news highlights FEPI's aggressive covered call strategy targeting AI and mega-cap tech names to generate its 25% yield, though analysts caution about NAV erosion risks during market downturns.
The outlook remains cautiously optimistic given the bullish technical setup and high income generation, but investors face significant risk from the concentrated tech portfolio and covered call strategy that limits upside potential. Market sentiment is divided between yield-seeking investors and those concerned about long-term NAV preservation in volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
